6.9 ~1-0 ~6-0 14 6.6 ~1'6 )5.0 * Virus stocks were titrated at various stages during the experiment both in Vero cells to determine the p.f.u, per ml and in 4-to 6-week-old outbred ICR Swiss mice to determine the LDso titres. The passage numbers of the unmutagenized or mutagenized viruses are indicated.
56 °C for 30 min), 1 ~ L-glutamine, and 0.1 ~ gentamicin. Vero 76 subclone E-6 ceils were used for routine assays of infectivity of virus stocks.
A total of 18 serial mutageneses were undertaken with ZH501, and 16 with ZH548. Mutagenesis consisted of growth of virus in the presence of 5-fluorouracil (5FU). From initial studies, the concentration of 200 lag 5FU per ml of culture fluid was selected for mutagenesis since this amount reduced infectious virus yields l0 z-to 103-fold by comparison to virus grown in the absence of the drug. The serial mutagenesis protocol was initiated with both the plaquecloned ZH501, and the uncloned ZH548 wild-type RVF virus strains. Monolayers of MRC-5 cells were inoculated with virus at a m.o.i, of 0.1 p.f.u./cell. Following a 1 h adsorption period, unadsorbed viruses were removed and the cell monolayers washed repeatedly with medium. After addition of new medium containing 200 lag 5FU per ml, the cells were incubated at 37.5 °C in an atmosphere of 5 ~o CO2. Desorbed virus was removed 3 to 4 h post-infection by replacing medium with fresh medium containing the same concentration of 5FU. Incubation was then continued for an additional 45 to 65 h. Culture supernatants were harvested and titrated by plaque assay on plates containing MRC-5 cells. The plaque assay overlay consisted of medium supplemented with 4~ heat-inactivated foetal bovine serum, 1 ~o L-glutamine and 0"5~o agarose (Seakem, FMC Marine Colloids Division, Rockport, Me., U.S.A.). After 3 days of incubation at 37 °C in a 5~ CO2 atmosphere, the plates were stained for 15 to 18 h by the addition of 0.01 ~o neutral red in a second agarose overlay medium. The two largest well-separated plaques from each titration were picked. Each was suspended in 0.5 ml of growth medium. Virus was eluted by vigorous agitation then left for 4 to 6 h at 4 °C or, alternatively, virus was eluted by one cycle of freeze-thawing. Stocks of virus from each suspension were grown in MRC-5 cells employing growth medium that lacked 5FU. Infected cell supernatants were harvested at 48 to 72 h postinfection, clarified by low-speed centrifugation, and stored in a freezer at -70 °C. One of the two virus stocks, chosen on the basis of its higher titre and/or larger plaque size, was then used to initiate a further round of mutagenesis. Control virus stocks were produced similarly, except that they were passaged in the absence of mutagen. * Virus stocks were titrated both in Vero cells to determine the p.f.u, per ml and in 4-to 6-week-old outbred ICR Swiss mice to determine the LDs0 titres. The passage numbers of the unmutagenized or mutagenized ZH548 virus stocks are indicated.
At various stages the virus stocks were tested for virulence in mice following intraperitoneal (i.p.) inoculation (Table 1 ). Virus pathogenicity was tested by inoculation of 0-1 ml of serial tenfold dilutions of virus stocks using groups of five or more 4-to 6-week-old ICR Swiss outbred mice. Mice were observed for 28 days or until death occurred. Virulence titres, expressed as the logarithm of the lethal dose that killed 50% of the mice (loglo LDso), were calculated by the method of Reed & Muench (1938) . Comparison of the p.f.u, numbers that correspond to 1 LDso for the viruses derived in each series, revealed that the unmutagenized ZH501 virus stocks were essentially unchanged in their relative virulence for the initial 16 passages. The mutagenized ZH501 stocks were observed to be a little less virulent, with two or three times more virus corresponding to 1 LDs0. For RVF virus ZH548 the original virus was also slightly less virulent than the ZH501 strain. The unmutagenized ZH548 stocks exhibited essentially similar virulence characteristics. By comparison, the mutagenized virus was severely attenuated even by passage 5, with 4.5 loglo p.f.u, of virus, or more, corresponding to an LDs0 ( Table 1 ).
Mice that survived the mutagenized ZH548 virus inoculations were challenged with virulent RVF virus ZH501 in an amount equivalent to a dose of between 100 and 500 mouse LDso units. For the passage 5, 8 and 14 viruses, complete protection through the 28 day period of observation was obtained for mice that had survived an initial inoculation with 102 to 103 p.f.u. (or more) of the mutagenized ZH548 virus. Mice that received less than 102 p.f.u, of the original mutagenized ZH548 virus were not protected. The reason why lower virus titres did not protect is not known.
Since the initial virulence and virus p.f.u, titrations were performed at different times and with different batches of mice, it was possible that some of the variations observed in p.f.u, per LD5o may have been due to differences in the animals that were used. For this reason the assays were repeated for the ZH548 series where evidence for attenuation had been obtained. The complete series of mutagenized ZH548 virus stocks up to passage 8 and then every other virus stock up to passage 16 (plus the original virus and three of the unmutagenized ZH548 virus stocks) were titrated in Vero cells and mice at the same time. This was also undertaken to establish whether the observed attenuation was progressive or whether it occurred at a unique step. The p.f.u, and LDs0 data are shown in Table 2 . For the unmutagenized and original ZH548 virus the p.f.u, required to give an LDso were estimated to be 10 to 100 although some attenuation was observed for the passage 16 virus stock. For the mutagenized viruses a progressive attentuation was obtained beginning at passage 3. By passage seven inoculation of even 10 6 p.f.u, was insufficient to kill 50% of the mice.
The titrations shown in Tables 1 and 2 are expressed in terms of LDs0 and p.f.u. Such results do not give information on the particular virulence characteristics observed for the different virus stocks. The data obtained for the analyses described in Table 2 were therefore analysed by the Reed & Muench (1938) method and plotted (Fig. 1) . The typical pattern for virulent RVF virus is represented by the parent (uncloned) ZH548 virus (Fig. I a) . The unmutagenized passage 1 and 8 virus stocks, despite having p.f.u, values per LDs0 comparable to that of the uncloned ZH548 (Table 2) , exhibited slightly different patterns of induced mortality. Mouse deaths lower than 100% were recorded over a 100 to 1000-fold virus dilution range in contrast to the tenfold dilution range obtained with the parent virus (Fig. 1) . These altered patterns of killing are characterized graphically by the differences in the slopes of the curves representing each virus. Similar results were obtained for the passage 16 unmutagenized virus stock, although the p.f.u. per LDs0 was approximately tenfold lower than that of the initial uncloned virus.
Dramatic shifts in virulence were evident for the mutagenized viruses as shown both by changes in p.f.u, per LDso (Table 1) and by changes in the slopes of the curves representing the different viruses. It was apparent from these data that changes in virulence occurred with almost every mutagenesis step. The results suggest that virus attenuation in the mutagenesis series was progressive and presumably the result of additional mutations in the viral genome. This conclusion is supported in part by oligonucleotide mapping of the passage 1, 8 and 12 mutagenized viruses and the observation of an oligonucleotide change in the passage 8 virus stock that was conserved in the passage 12 virus stock with an additional change in the latter virus that was not present in the earlier viruses (Fig. 2) . No oligonucleotide changes were observed in the unmutagenized virus (data not shown).
In view of the potential value of the attenuated virus for vaccine development, other biological properties have been analysed. The growth kinetics of the passage 12 mutagenized virus were found to be similar to those of the original ZH548 virus stocks with maximum yields (7 to 8 log10 p.f.u./ml) obtained between 24 and 48 h post-infection. The plaques produced in Vero cell monolayers by the passage 12 mutagenized virus were of uniform size, about 2 to 2.5 mm in diameter, corresponding to approximately half that obtained with the parent virus under the same plaque assay conditions. Other strains of RVF virus which have been reported to be attenuated yield plaques that do not exceed 0.5 ram. These include the naturally attentuated Lunyo virus (a strain of RVF virus; Weinbren et al., 1957) and the laboratory-attenuated minute plaque variant of ZH501 (Moussa et al., 1982) . Both viruses are avirulent for adult mice when inoculated by the i.p. route. However, Peters & Anderson (1981) have found no consistent correlation between plaque size and virulence in mice for several randomly selected clones t~ .-o recovered from a ZH501 virus pool, Also the widely employed laboratory-attenuated Smithburn vaccine strain of RVF virus produces a spectrum of plaque sizes resembling that of its parent. The attenuated virus was neutralized in vitro to levels comparable to that obtained with the parent virus when polyclonal antisera prepared to either RVF virus strain ZH548 or ZH501 were used for virus neutralization. The virus was similarly neutralized by several monoclonal antibodies prepared to the envelope glycoproteins of ZH501 (I. Tappert, unpublished results).
The approach presented here to obtain attenuated viruses for use as live virus vaccines has not been reported before. The method used previously for the derivation of attenuated viruses has involved the serial unselected passage of a virulent virus either in cell culture or by employing various heterologous animals hosts. Presumably, where this approach has been successful variant viruses with mutations in their genomes were recovered which, for one reason or another, exhibited diminished disease capability in their natural hosts. We have taken this conventional procedure a logical step further by increasing the rate of mutation by employing a chemical mutagen, 5-fluorouracil. The possibility of deriving a phenotypically stable attenuated virus by intensive mutagenesis was suggested by experiments with the rhabdovirus vesicular stomatitis virus (VSV, Clewley & Bishop, 1979) . For mice a 3 to 4 log10 drop in the LD5o to p.f.u. ratio was noted when VSV was subjected to 23 serial mutagenesis passages in a manner similar to those described here. Furthermore, ribonuclease TI oligonucleotide fingerprint analyses of virus stocks from those passages indicated a rapid accumulation of mutations in the viral genome during mutagenesis.
The progressive attenuation of the virus clones derived from serial mutagenesis of the ZH548 virus may be correlated with an accumulation of mutations in the viral genome. The progressive changes in virulence that have been observed support our conclusion that multiple mutations have contributed to attenuation of the mutagenized virus. Whether this means that reversion to virulence will be less probable remains to be determined. The effective attenuation of the ZH548 virus was not paralleled by similar attenuation in the ZH501 virus. We interpret this to indicate that ZH501 is genetically more resistant to change by comparison to ZH548. Whether this reflects a difference in the error rate of the viral replicases of the two viruses is not known.
The results reported here involving the serial mutagenesis of ZH548 virus, taken together with the earlier experiments reported with VSV, suggest the wider applicability of this method for achieving rapid attenuation of viruses for use in live virus vaccine development. Experiments concerning the attenuated character of the derived ZH548 viruses involving other hosts including primates and pregnant sheep will be reported in a subsequent communication. Experiments to elucidate the structural and functional differences between the passage 12 attenuated ZH548 virus and its virulent parent are in progress. Such analyses may also contribute to an understanding of the factors involved in the pathogenicity of RVF virus.
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